Ascendis Pharma A/S Ordinary Share Earnings Dividend

Ascendis Pharma A/S Ordinary Share’s revenue jumped 148.29% since last year same period to $250.66Mn in the Q1 2026. On a quarterly growth basis, Ascendis Pharma A/S Ordinary Share has generated 2.23% jump in its revenue since last 3-months.

Ascendis Pharma A/S Ordinary Share’s net profit jumped 776.02% since last year same period to $639.69Mn in the Q1 2026. On a quarterly growth basis, Ascendis Pharma A/S Ordinary Share has generated 2024.03% jump in its net profits since last 3-months.

Ascendis Pharma A/S Ordinary Share’s net profit margin jumped 372.27% since last year same period to 255.21% in the Q1 2026. On a quarterly growth basis, Ascendis Pharma A/S Ordinary Share has generated 1981.99% jump in its net profit margins since last 3-months.

Ascendis Pharma A/S Ordinary Share’s price-to-earnings ratio after this Q1 2026 earnings stands at 26.26.

Ascendis Pharma A/S Ordinary Share’s earning per share (EPS) estimates for the current quarter stand at 1.13 - a 162.79% jump from last quarter’s estimates.

Ascendis Pharma A/S Ordinary Share’s earning per share (EPS) estimates for the current year stand at 1.13.

Ascendis Pharma A/S Ordinary Share’s earning per share (EPS) jumped 117.09% since last year same period to 0.27 in the Q1 2026. This indicates that the Ascendis Pharma A/S Ordinary Share has generated 117.09% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ascendis Pharma A/S Ordinary Share’s return on assets (ROA) stands at -0.01.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ascendis Pharma A/S Ordinary Share’s return on equity (ROE) stands at 0.33.